Literature DB >> 7529227

Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase.

J K Liao1, W S Shin, W Y Lee, S L Clark.   

Abstract

The atherogenic effects of low-density lipoprotein (LDL) may be mediated, in part, by its effect(s) on endothelial-derived nitric oxide (NO). To determine whether LDL can modulate NO production by changing NO synthase expression, we treated human saphenous vein endothelial cells with increasing concentrations of native or oxidized LDL (0-100 micrograms/ml) for various durations (0-72 h). Oxidized, but not native LDL caused a time-dependent decrease in steady-state NO synthase mRNA levels. This coincided with a maximal 56% decrease in NOS activity was determined by [3H]arginine to [3H]citrulline conversion. In the presence of actinomycin D, treatment with oxidized LDL reduced the half-life of NO synthase mRNA from 36 to 10 h. This decrease in NO synthase mRNA correlated with the degree of LDL oxidation and was attenuated by pretreatment with cycloheximide. Nuclear run-off studies showed a biphasic transcriptional pattern of NO synthase gene with an initial 25% decrease during the first 6 h followed by a maximal 2.2-fold increase over baseline during the subsequent 18 h. These results indicate that oxidized LDL regulates endothelial NOS expression through a combination of early transcriptional inhibition and post-transcriptional mRNA destabilization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529227     DOI: 10.1074/jbc.270.1.319

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy.

Authors:  R G Schwartz
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 2.  Flow, NO, and atherogenesis.

Authors:  John P Cooke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

3.  Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy.

Authors:  A Ozkiris; K Erkiliç; A Koç; S Mistik
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

Review 4.  Rho-kinase: a potential link between hypercholesterolemia and abnormal vascular smooth muscle contraction.

Authors:  James K Liao
Journal:  Circ Res       Date:  2006-08-04       Impact factor: 17.367

Review 5.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Phytoestrogen alpha-zearalanol antagonizes oxidized LDL-induced inhibition of nitric oxide production and stimulation of endothelin-1 release in human umbilical vein endothelial cells.

Authors:  Hai-Shan Xu; Jinhong Duan; Shunling Dai; Yunqing Wu; Renyu Sun; Jun Ren
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

7.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.

Authors:  R De Caterina; P Libby; H B Peng; V J Thannickal; T B Rajavashisth; M A Gimbrone; W S Shin; J K Liao
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

9.  Lipoproteins modulate expression of the macrophage scavenger receptor.

Authors:  J Han; A C Nicholson
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Association of NOS3 Glu298Asp SNP with hypertension and possible effect modification of dietary fat intake in the ARIC study.

Authors:  Pascal L Kingah; Hung N Luu; Kelly A Volcik; Alanna C Morrison; Jennifer A Nettleton; Eric Boerwinkle
Journal:  Hypertens Res       Date:  2009-12-04       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.